Trial Profile
Phase II study of ZYN-001 in Tourette Syndrome.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 09 Jan 2018
Price :
$35
*
At a glance
- Drugs ZYN 001 (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Therapeutic Use
- 09 Jan 2018 New trial record
- 03 Jan 2018 According to the Zynerba Pharmaceuticals media release, company expects to initiate this trial late in the second half of 2018.